Diabetes is a chronic, progressive disease that affects approximately 347 million people worldwide. According to the International Diabetes Federation, diabetes incidence rates are mounting, particularly in countries where a sedentary lifestyle and obesity are on the rise. Without significant intervention, one person in ten will have diabetes by 2030.
Type 2 is the most common form of diabetes; it is also known as non-insulin diabetes or adult-onset diabetes and accounts for 90 percent of all cases.
In addition to older age, other risk factors for diabetes include being obese, having a family history of diabetes, impaired glucose metabolism, and a sedentary lifestyle. African Americans, Hispanic/Latino Americans, American Indians, and some Asian Americans and Native Hawaiians or Other Pacific Islanders are at particularly high risk for type 2 diabetes and its complications.
A number of studies have shown that regular physical activity can significantly reduce the risk of developing type 2 diabetes. It is also an important part of a healthy lifestyle for people with type 2 diabetes. People of all ages – with and without diabetes – can benefit from physical activity, according to the U.S. Centers for Disease Control and Prevention.
Healthier eating and weight loss can also help delay or prevent the onset of diabetes, according to a major study funded by the U.S. government. Eat three to five servings of fruits and vegetables a day and reduce consumption of sugar and saturated fats.
Copyright © 2009-2016 Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc. All rights reserved.
This website of Merck & Co., Inc., Kenilworth, NJ, USA (the “company”) includes “forward-looking statements” within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. These statements are based upon the current beliefs and expectations of the company’s management and are subject to significant risks and uncertainties. There can be no guarantees with respect to pipeline products that the products will receive the necessary regulatory approvals or that they will prove to be commercially successful. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements.
Risks and uncertainties include, but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of pharmaceutical industry regulation and healthcare legislation in the United States and internationally; global trends toward healthcare cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; the company’s ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of the company’s patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and/or regulatory actions.
The company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Additional factors that could cause results to differ materially from those described in the forward-looking statements can be found in the company’s 2015 Annual Report on Form 10-K and the company’s other filings with the Securities and Exchange Commission (SEC) available at the SEC’s Internet site (www.sec.gov).
The information contained in this website was current as of the date presented. The company assumes no duty to update the information to reflect subsequent developments. Consequently, the company will not update the information contained in the website and investors should not rely upon the information as current or accurate after the presentation date.